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Hematopoietic stem cell transplantation (HSCT) is a treatment option for both malignant and nonmalignant
disorders. HSCT patients remain at high risk for multiorgan failure, with previous studies noting mortality
rates exceeding 90% when mechanical ventilation (MV) is required. We propose that advancements in critical
care management and HSCT practices have improved these dismal outcomes. We performed a retrospective
review of admissions to our bone marrow transplant unit between 2006 and 2010. All HSCT recipients
requiring admission to the bone marrow transplant unit who received MV or renal replacement therapy (RRT)
were evaluated. A total of 68 patients required MV. Twenty patients required RRT, all of whom required MV.
Fifty-nine of the 68 ventilated patients died, for an overall mortality rate of 86.8%. The presence of renal
failure and concomitant respiratory or liver dysfunction at the time of intubation was associated with
a mortality rate of 100%. High mortality persists in our HSCT population requiring artiﬁcial support despite
overall advances in critical care and HSCT practices. Critical care triage and management decisions in this
high-risk population remain challenging.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) offers
improved remission and ultimately curative rates for those
with hematologic malignancies compared with standard
chemotherapeutic regimens. The number of patients
undergoing HSCT has continued to increase, and HSCT is now
performed for a multitude of malignant and nonmalignant
diseases [1]. The 2010 Center for International Blood and
Marrow Transplant Research report includes data on more
that 16,000 HSCTs performed in 2009 and more than
300,000 since the 1970s [2].
The HSCT process and subsequent posttransplantation
course are often complicated by the development of both
infectious and noninfectious problems. Unfortunately, organ
dysfunction/failure is common, possibly related to intensive
conditioning regimens, continued immunosuppression, and
underlying disease process [3]. The development of life-
threatening organ failure commonly results in admission to
an intensive care unit (ICU), with respiratory complications
accounting for up to 60% of ICU admissions [4], often
requiring mechanical ventilation (MV). Acute renal failure
and the need for renal replacement therapy (RRT) accounts
for another 25% [5,6].dgment on page 324.
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overall poor outcomes and receive varying amounts of arti-
ﬁcial support. Previous studies of HSCT patients requiring
some form of artiﬁcial support (respiratory, renal, or hemo-
dynamic) have reported mortality rates ranging from 73% to
100% [5,6-9]. Secondary to these high mortality rates, the
proper triage of these patients remains controversial, with
some believing that continued critical care support is war-
ranted unless the underlying malignancy is untreatable
[4,8,10,11] and others believing that advanced life support in
the setting of 100% mortality merely prolongs the dying
process [12]. In the last decade, multiple advances in critical
care and stem cell transplantation have led to increased
overall survival [13,14]. This change may be attributed to
overall advances in the understanding and management of
critically ill patients through increased awareness of venous
thromboembolism, prevention of nosocomial infections, and
use of care “bundles” [15-18].
Numerous previous studies have examined the impact of
MV and RRT independently on morbidity and mortality, but
little has been published on the combination of both
supportive options in HSCT recipients. We hypothesized that
overall advances in the care of these patients have resulted in
improved outcomes for HSCT recipients compared with
studies published in the 1990s. We also hypothesized that
the Sequential Organ Failure Score (SOFA) score would be
useful in predicting mortality in HSCT recipients requiring
MV and/or RRT.
MATERIALS AND METHODS
We performed a retrospective chart review of patients admitted to our
14-bed bone marrow transplant unit (BMTU) between January 2006 and
December 2010 who required MV or RRT. All HSCT recipients requiring
hospital admission are admitted to the BMTU in the transplantation and
Figure 1. Flow diagram of eligible patients and outcomes.
Table 1
Patient Demographic Data
All
Patients
(n ¼ 68)
Survivors
(n ¼ 9)
Nonsurvivors
(n ¼ 59)
P
Value
Age, years, mean
(SD)
53.5 (15.1) 56.8 (9.3) 53 (15.8) .91
BMI, kg/m2, mean
(SD)
28 (8.0) 23 (6.1) 28.8 (8.0) .041
Sex, n (%) .73
Female 28 (41) 3 (4) 25 (37)
Male 40 (59) 6 (9) 34 (50)
Indication for HSCT,
n (%)
.40
Leukemia 34 (50) 2 (3) 32 (47)
Lymphoma 12 (18) 2 (3) 10 (15)
Myeloma 8 (12) 1 (1) 7 (10)
Other 14 (20) 4 (6) 10 (15)
Type of
transplantation,
n (%)
.82
Allogeneic 63 (93) 8 (12) 55 (81)
Autologous 5 (7) 1 (1) 4 (6)
Table 2
Ventilator and Hospital Stay Data
All Patients Survivors Nonsurvivors P Value
Ventilator days 17.1 (16.9) 12.4 (15.3) 17.8 (17.2) .35
Ventilator-free days 19.0 (49) 20.7 (14.2) 18.8 (52.4) .004
Hospital stay, days 51.4 (37.1) 42.2 (16.1) 52.8 (39.3) .96
Days from HSCT to
respiratory failure
140 (357) 102 (118) 146 (381) .81
Values are mean (SD).
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patients and thus an HSCT recipient who becomes critically ill is not
transferred to the medical ICU. All patients are admitted to the hematologic
malignancy service in the BMTU under the care of board-certiﬁed medical
oncologists with special interest in bone marrow transplantation. In the
event of critical illness, multidisciplinary care with board-certiﬁed critical
care specialists and nephrologists is provided, along with standardized,
hospital-wide critical care protocols.
Inclusion criteria for this study included admission to the BMTU, need
for MV or RRT, and history of HSCT. Patients who were receiving MV or RRT
before undergoing HSCT were excluded. There were no other exclusion
criteria. We collected data from patient charts including demographic
information, indication for HSCT, type and timing of HSCT, duration of MV,
ventilator-free days post-MV, use of noninvasive MV, duration and type of
RRT, SOFA score at the initiation of MV or RRT, use of tracheostomy and/or
percutaneous gastric (PEG) feeding tube, performance of bronchoscopy and
results, and mortality (30-day, hospital discharge, and overall mortality at
follow-up). In patients who were intubated more than once, the last intu-
bation was used for ﬁnal outcome analysis regarding mortality.
Thomas Jefferson University Hospital’s Institutional Review Board
approved this study. All statistical analyses were performed with Stata 10
(StataCorp, College Station, TX). Simple descriptive statistics were used to
describe the patient population and ﬁndings. The 2-sided Fisher exact test
was used to compare dichotomous variables, and the 2-sample Wilcoxon
rank sum test was used to compare nonparametric variables.
RESULTS
A total of 319 HSCTs were performed during the 5-year
study period. Sixty-eight patients (21.3%) developed respi-
ratory failure requiring MV, and 20 patients (6.3%) developed
renal failure requiring RRT (Figure 1). All patients requiring
RRT received concomitant MV.
The 30-day, hospital, and overall mortality rates for all
patients requiringMVwere 55.8% (38 of 68), 63.2% (43 of 68),
and 86.8% (59 of 68), respectively. For those patients
requiring both MV and RRT, 30-day, hospital, and overall
mortality was 60% (12 of 20), 90% (18 of 20), and 100% (20 of
20), respectively. The overall mortality of patients requiring
MV but not RRT was 81.3% (39 of 48).
Patient demographic data are displayed in Table 1. For all
patients, the average age at intubation was 53.5 years, and
average body mass index (BMI) was 28 kg/m2. There was
a statistically signiﬁcant difference in BMI between survivors
and nonsurvivors (23 kg/m2 versus 28.8 kg/m2; P ¼ .041).
RRT was performed in 20 patients, all of whom required
concomitant MV. All 20 patients required continuous veno-
venous hemodialysis at the time of RRT initiation, with 5
patients subsequently undergoing intermittent hemodialysis
while hospitalized. No patient underwent kidney biopsy as
part of the evaluation of renal failure. The mean duration of
RRT was 13.9 days (range, 1-34 days) in the 18 patients who
survived for less than 35 days. Two patients receiving RRT
survived for more than 35 days. One of these patients wasdischarged to a skilled nursing facility after an initial 140-day
hospitalization, because he was unable to perform activities
of daily living. Shortly thereafter, he was readmitted to the
BMTU, and was subsequently discharged to home hospice
care. The other patient developed acute renal failure
requiring RRT with initial recovery and subsequent discharge
to home. Over the next 100 days, he was readmitted 4 times
with failure to thrive, recurrent sepsis, and renal failure, and
he ultimately died in the BMTU after refusing renal
replacement therapy.
Ventilator support data are displayed in Table 2. Themean
duration of MV was 17.1 days (range, 1-54 days). Thirteen
patients required more than one intubation, with only 1 of
these patients surviving to hospital discharge. Noninvasive
ventilation modalities were attempted in 10 patients, all of
whom subsequently required intubation. Five patients were
electively intubated for procedures, 2 for an exploratory
laparotomy (with both subsequently dying) and 3 for
surgical lung biopsy (with only 1 surviving). Twenty-seven
patients received a tracheostomy, and 17 patients received
a concomitant PEG tube. Only 1 patient survived after these
procedures (with both a tracheostomy and a PEG tube), for an
overall survival of 3.7% (1 of 27). No patient death was
directly attributable to a procedure. No patient was intubated
to facilitate bronchoscopy.
A total of 29 bronchoscopies were performed in 27
patients. A positive bronchoscopy result was identiﬁed in 12
patients, for a yield of 41.4%. The most common yields were
bacterial (n ¼ 7) and fungal (n ¼ 4). Twenty-three of the 27
patients who underwent bronchoscopy subsequently died
(85.2% mortality). Of the bronchoscopy cultures from our 4
survivors, 2 were nondiagnostic, 1 recovered Candida albi-
cans, and 1 recovered Staphylococcus epidermis.
Table 3
SOFA Scores at the Time of Intubation for Survivors and Nonsurvivors
Survivors Range Nonsurvivors Range P Value
Total 7.7, [7], (3.1) 4-14 11.6, [11.5],
(4.4)
5-20 .009
Lung 2.6, [2.5], (1.2) 1-4 2.5, [3], (1.1) 0-4 .95
Renal 0.7, [1], (0.7) 0-2 1.5, [1], (1.5) 0-4 .17
Liver 0.1, [0], (0.3) 0-1 1.4, [1], (1.4) 0-4 .004
Cardiovascular 0.9, [0], (1.3) 0-3 1.6, [1], (1.5) 0-4 .15
Hematologic 1.6, [2.5], (1.6) 0-4 3.1, [3], (0.8) 1-4 .01
Central
nervous
system
1.8, [2.5], (1.4) 0-3 1.5, [1], (1.3) 0-4 .53
SOFA scores based on organ dysfunction range from 0 to 24 for total
score and from 0 to 4 for each component. Scores are presented as mean
[median] (SD).
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(range, 4-20). Mean SOFA scores available at the time of
intubation for survivors and nonsurvivors are displayed in
Table 3. The mean SOFA score was signiﬁcantly lower
in survivors compared with nonsurvivors (7.7 versus 11.6;
P¼ .009). Evaluation of the separate components of the SOFA
score revealed signiﬁcant differences between survivors and
nonsurvivors in both liver and hematologic dysfunction
scores. The mean liver score was 0.1 for survivors and 1.4 for
nonsurvivors. There were no survivors if liver dysfunction
was present at the time of intubation (liver SOFA score >1).
The mean hematologic score was 1.6 for survivors and 3.1 for
nonsurvivors. SOFA scores for other organ dysfunctions,
including renal dysfunction, were not statistically signiﬁ-
cantly different between survivors and nonsurvivors.DISCUSSION
Our ﬁndings show an extremely high mortality rate for
critically ill HSCT recipients requiring artiﬁcial support. We
found 100% mortality in HSCT recipients requiring MV and
RRT or MV with evidence of liver dysfunction (total bilirubin
2) at the time of intubation. Similar to previous studies,
here simply the need for MV was associated with a high
mortality rate (86.8%). The vast majority of those previous
studies were performed in the late 1990s, however, and there
have been numerous improvements in critical care since that
time, including lowetidal volume ventilation and early goal-
directed therapy. Nonetheless, based on our data, it does not
appear that improvements in the general care of critically ill
patients and adoption of these hospital-wide protocols have
translated into signiﬁcant improvement in overall survival
rates in this patient population. Unfortunately, the develop-
ment of organ dysfunction after HSCT, speciﬁcally respiratory
failure and renal failure, continues to portend a high risk of
death.
We believe that the present study continues to add
important data identifying the exceedingly high mortality
rate in HSCT recipients who develop organ failure, particu-
larly respiratory and renal failure. In some previous studies of
HSCT recipients requiring MV or RRT, the data conﬁrm our
ﬁndings of high mortality in small subsets of patients
requiring MV and RRT. Parikh et al. [5] assessed the impact of
renal failure in nonmyeloablative HSCT recipients and iden-
tiﬁed 12 patients in their cohort who required both MV and
RRT, only 2 of whom survived to hospital discharge. Hahn
et al. [6] identiﬁed 12 patients in their cohort who developed
acute renal failure requiring RRT and also required MV, with
100% mortality. Jackson et al. [10] identiﬁed 8 patients in
their cohort who required initial intubation and RRT, with 3survivors (37.5% survival rate). They also identiﬁed a pop-
ulation requiring RRT, MV, and hemodynamic support, in
whom mortality was 91.6% (11 of 12). The major difference
between that study and ours is that Jackson et al. had survival
data available only for initial intubations and ICU admission,
and not always for hospital stay and overall outcomes.
Numerous studies have conﬁrmed that multiorgan failure
predicts worse outcomes in HSCT recipients [8,9,11,19-21].
Unfortunately, prediction rules and organ failure scoring
systems have demonstrated conﬂicting results in predicting
survival of this population. The SOFA score has demonstrated
some ability to predict mortality in HSCT recipients [22,23].
Our analysis conﬁrms a statistically signiﬁcant difference in
overall SOFA scores between survivors and nonsurvivors at
the timeof intubation. Thisdifference isnotunexpected, given
that patients with higher SOFA scores had more organ failure
(in both quantity and quality) and would be expected to
have greatermortality. Amore useful observationwould have
been the delineation of a speciﬁc SOFA score that would have
been predictive of mortality/survival. This was not possible in
our cohort, however, because the SOFA scores ranged widely,
from 4 to 16 in survivors and from 5 to 20 in nonsurvivors.
This broad range of scores likely would make it difﬁcult to
base clinical decisions on a speciﬁc SOFA score.
The SOFA scoring system was not initially designed to
analyze each organ system in isolation; however, it does
provide a sense of speciﬁc organ dysfunction/failure. Sub-
analysis of SOFA organ scores demonstrated statistically
signiﬁcant differences between survivors and nonsurvivors.
The presence of elevated bilirubin (indicating liver dysfunc-
tion) and thrombocytopenia (indicating hematologic
dysfunction) were both associated with death. Furthermore,
all HSCT recipients who required MV and had liver
dysfunction died (27 of 27; 100%).
An interesting ﬁnding is the signiﬁcant difference in BMI
between survivors and nonsurvivors. Mean BMI was signif-
icantly lower in patients surviving MV (23 kg/m2 versus
28.8 kg/m2). This ﬁnding contradicts previously reported ICU
data suggesting that elevated BMI actually may be protective
in critically ill patients [24]; however, that same study sug-
gested that those patients with higher BMI are also at
increased risk for multiorgan dysfunction and increased
length of hospital stay. Previous studies in allogeneic HSCT
recipients have not been able to correlate obesity with
increasedmortality rates [25]. The small number of survivors
in our cohort makes it difﬁcult to draw any signiﬁcant
conclusions from this ﬁnding; however, it remains inter-
esting, and further study may be warranted.
The utility of invasive procedures for our study pop-
ulation remains uncertain. No patients with renal failure
requiring RRT underwent kidney biopsy during evaluation
and treatment. The reason for this is not entirely clear and
might be related to an institutional bias; however, it may not
have signiﬁcant clinical relevance. A retrospective review of
autopsy studies in HSCT recipients requiring RRT offered no
clinicopathological answer for renal failure in most speci-
mens [26]. The survival rate was extremely low (3.7%) in
patients undergoing tracheostomy and/or PEG tube place-
ment. Mortality was 80% in patients electively intubated
for procedures in the operating room and 85.2% in
those undergoing bronchoscopy. Unfortunately, these poor
outcomes may reﬂect the overall illness of the patients and
their need to undergo these procedures; however, our small
sample size precludes us from analyzing this possibility
further.
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nature and the inherent bias in a retrospective study. This
was a single-center study, and our results might not be
generalizable to other ICUs and BMTUs. Another limitation
may be our current bed management of critically ill HSCT
recipients, including our policy that directs admission to
a BMTU, not to a medical ICU. However, we provide multi-
disciplinary care of these patients with the help of inten-
sivists, medical oncologists, nephrologists, and numerous
other medical and surgical specialties. Much of the care
remains driven by care bundles and evidence-based proto-
cols, as well as multidisciplinary care. The literature also
supports a signiﬁcantly increased risk of death in HSCT
recipients who become critically ill. This is consistent with
our data, and thus we believe that our ﬁndings are general-
izable to other institutions serving this critically ill pop-
ulation. Other limitations include a lack of data on code
status at the time of death, reason for death, and status of
transplantation (eg, full engraftment, recurrence) at the time
of critical illness, which might have affected decisions
regarding aggressiveness of care.
Initial research of critically ill HSCT recipients in the 1990s
reported 100% mortality in those developing acute lung
injury along with renal failure and hepatic failure [12]. In this
review of our data along with the currently available litera-
ture, we are intending not to suggest that all HSCT recipients
should be denied MV and/or RRT, but rather to impart
a cautionary tale to healthcare providers regarding the
evidence-based outcomes within this patient population.
The healthcare team and patient should be aware of the poor
prognosis associated with the need for artiﬁcial support in
HSCT recipients. Critical care triage and management deci-
sions in this high-risk population remain difﬁcult, and frank
discussions with potential HSCT recipients and families are
needed. Given the overall goals of HSCT include cure of the
underlying disease process and return to an acceptable
quality of life, prolonged artiﬁcial support in the setting of
100% mortality does not seem appropriate.ACKNOWLEDGMENT
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